Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P16 | ISIN: SE0022419784 | Ticker-Symbol: 61L0
Frankfurt
17.09.25 | 08:25
28,240 Euro
-0,63 % -0,180
1-Jahres-Chart
SECTRA AB Chart 1 Jahr
5-Tage-Chart
SECTRA AB 5-Tage-Chart
RealtimeGeldBriefZeit
28,00028,52017.09.
PR Newswire
268 Leser
Artikel bewerten:
(1)

Three French healthcare providers digitize pathology with Sectra to enhance collaboration and cancer diagnostics

LINKÖPING, Sweden, Aug. 21, 2025 /PRNewswire/ -- Three university hospitals from a large region in France have signed contracts with international medical imaging IT and cybersecurity company Sectra (STO: SECT.B) to digitize their pathology workflows. Replacing microscopes with a digital workflow is a step towards closer collaboration across the sites and to further enhance cancer diagnostics in the region.

Digitizing pathology is part of a broader initiative to bring regional university hospitals closer together through joint strategies. Sectra's solution supports the long-term goals of improved efficiency and equitable patient access to high-quality diagnostics across the region.

By replacing microscopes with a digital workflow, the pathologists get instant, and when needed, remote access to digital images of tissue samples. Sectra's solution combines worklists, reporting, and image review in a single application optimized for primary diagnostics. It also enables the healthcare providers to utilize AI to further improve pathology workflows and cancer care.

"Moving towards closer collaboration between healthcare providers in pathology is becoming increasingly important in France. Not only to manage rising workloads, but to ensure equal access to sub-specialist expertise. A digital solution provides the tools to deliver consistent, high-quality cancer diagnostics and facilitates collaboration as it's easier to share the cases," says Fabien Lozach, President of Sectra in France.

The contracts, signed in June 2025, include Sectra's digital pathology module. The three healthcare providers together perform approximately 85,000 pathology examinations annually. The solution will also be integrated with each hospital's laboratory information system (LIS) for a streamlined and efficient workflow.

The digital pathology module is part of Sectra's enterprise imaging solution that provides a unified strategy for all imaging needs in one single system, thus both improving outcomes as well as lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise without acquiring a new back end. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS".

About Sectra

Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2024/2025 fiscal year totaled SEK 3,240 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website. For more information, visit Sectra's website.

For further information, please contact:
Dr. Torbjörn Kronander,
CEO and President Sectra AB,
46 (0) 705 23 52 27

Marie Ekström Trägårdh,
Executive Vice President Sectra AB and President Sectra Imaging IT Solutions,
46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/three-french-healthcare-providers-digitize-pathology-with-sectra-to-enhance-collaboration-and-cancer,c4219983

The following files are available for download:

https://news.cision.com/sectra/i/sectra-s-digital-pathology-solution,c3461581

Sectra's digital pathology solution

Cision View original content:https://www.prnewswire.co.uk/news-releases/three-french-healthcare-providers-digitize-pathology-with-sectra-to-enhance-collaboration-and-cancer-diagnostics-302535578.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.